Cargando…
LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
Background and Purpose: Sedation and somnolence remain serious adverse effects of the existing analgesics (e.g., pregabalin, duloxetine) for neuropathic pain. The available evidence indicates that serotonin (5-HT), noradrenaline (NE), and dopamine (DA) play important roles in modulating the descendi...
Autores principales: | Li, Nannan, Li, Chunmei, Han, Rui, Wang, Yu, Yang, Mina, Wang, Hongbo, Tian, Jingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382704/ https://www.ncbi.nlm.nih.gov/pubmed/30837867 http://dx.doi.org/10.3389/fphar.2019.00053 |
Ejemplares similares
-
The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats
por: Zhang, Renyu, et al.
Publicado: (2014) -
Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor
por: Zhang, Fangxi, et al.
Publicado: (2016) -
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
por: Welsch, Patrick, et al.
Publicado: (2018) -
Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI)
por: Takata, Junko, et al.
Publicado: (2019) -
Serotonin and Noradrenaline Reuptake Inhibitors Improve Micturition Control in Mice
por: Redaelli, Marco, et al.
Publicado: (2015)